|
Endo Announces Positive Results from Phase 3 Studies of Collagenase Clostridium Histolyticum (CCH) in Patients …
PR Newswire UK (press release) 7, 2018 /PRNewswire/ — Endo International plc (NASDAQ: ENDP) announced positive results today from two identical Phase 3 RELEASE* studies of collagenase clostridium histolyticum (CCH) for the treatment of cellulite in the buttocks. Subjects receiving … |
Read more: www.prnewswire.co.uk
Investor’s Business Daily |
Endo Plans For Cellulite Drug In 2020 â Here's Why Investors Balked
Investor’s Business Daily Xiaflex treats a disease that causes painful erections and a condition that can hinder proper finger movement. For the year, Endo expects to earn $2.65-$2.75 per share, excluding items, on $2.87 billion to $2.92 billion in sales. The low end of both … Endo International Plc – ENDP – Stock Price Today – ZacksZacks |
Digital Journal |
Director Of Dermaline Explains Carboxytherapy for Cellulite
Digital Journal The female hormone estrogen causes these fat cells to store fat, whereas the male hormone testosterone stimulates the fat cells to break down fat. So, women are genetically superior at storing energy in the form of fat to provide energy during pregnancy. |
Read more: www.digitaljournal.com
